Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).

Feature | Coronavirus (COVID-19) | By Dave Fornell, Editor

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine

A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA) COVID-19 ...

June 24, 2021

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

News | Cardiovascular Clinical Studies

Study Shows ACC Registry Data Could Support Cardiac Clinical Trials

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) regis ...

June 24, 2021

Feature | Coronavirus (COVID-19)

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination

June 23, 2021 — Findings from a small study detailing the treatment of myocarditis-like symptoms in seven people after ...

June 23, 2021

The Philips Healthcare SyncVision system co-registers iFR hemodynamic blood flow measurements to live angiograms to enable easier assessment of which lesions in a vessel need to be stented and which can be left alone and treated medically.

News | FFR Technologies

First Patient Enrolled in DEFINE GPS Study to Assess PCI Guided by Co-registered iFR Versus Angiography

June 22, 2021 – Philips Healthcare announced the official start of the DEFINE GPS study, with the first patient being ...

June 22, 2021

Boston Scientific Makes a Comeback With Positive Clinical Data With its Second Iteration Acurate neo2 TAVR Valve

Blog | Structural Heart

Boston Scientific Makes a Comeback With Positive Clinical Data for its Second Iteration Acurate neo2 TAVR Valve

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...

June 08, 2021

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Feature | ACC | By Dave Fornell, Editor

Key Cardiology Technology Takeaways at ACC 2021

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

June 08, 2021

Two years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at ACC.21.

News | Peripheral Artery Disease (PAD)

SAFE-PAD Study Shows No Safety Issues With Paclitaxel-coated Devices In Peripheral Artery Disease

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

June 07, 2021

The HLT, Bracco, Meridian II TAVR Valve System.

Feature | Structural Heart | Dave Fornell, Editor

Bracco Moving Forward With HLT Meridian TAVR Valve

June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic ...

June 02, 2021

Feature

June 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magaz ...

June 01, 2021

The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System. #EuroPCR #EuroPCR21 #EuroPCR2021

Feature | Structural Heart

Acurate neo2 TAVR Valve Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates

May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated ...

May 26, 2021

RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. #ACC21 #ACC2021

News | Heart Failure

Type of Heart Failure May Influence Optimal Approach for AFib Rhythm Control Versus Rate Control Strategy

May 19, 2021 — Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on ...

May 19, 2021

ECMO unit in use to support a severely ill patient at the University of Michigan. ECMO was shown to imporve survival and neuro outcomes in sudden cardiac arrest patients who do not respond to standard therapy.

Feature | Sudden Cardiac Arrest

ECMO Increased Survival in Refractory Out-of-Hospital Cardiac Arrest

May 19, 2021 — A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to ...

May 19, 2021

$The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021$

Feature | Coronavirus (COVID-19)

AI Derived Cardiac Echo Measurements Able to Predict COVID-19 Mortality

May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortal ...

May 18, 2021

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

News | Heart Failure

GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

May 18, 2021

News | Coronavirus (COVID-19)

Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

May 18, 2021